<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995354</url>
  </required_header>
  <id_info>
    <org_study_id>MucoCU</org_study_id>
    <nct_id>NCT04995354</nct_id>
  </id_info>
  <brief_title>Efficacy of EGF-loaded Self Healing Gel in Treatment of Oral Mucositis</brief_title>
  <official_title>Self Healing Gel as a Vehicle for Recombinant Human Epidermal Growth Factor in Treatment of Oral Mucositis Following Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer treatment, including radiation along with aggressive chemotherapy, increases the&#xD;
      patient's survival rate. However, they possess toxic side effects. Oral mucositis is one of&#xD;
      the most serious complications of cancer treatment, which occurs in most of patients&#xD;
      receiving cancer therapy. Mucositis can dramatically affect the patient's quality of life&#xD;
      .Epidermal growth factor (EGF) is a dominant factor in early keratinocyte differentiation,&#xD;
      proliferation and migration. However, a major obstacle in most studies is that there isn't&#xD;
      prolonged contact between the applied treatment and the oral mucosa to achieve the optimum&#xD;
      therapeutic effect. Thus, a new vehicle for EGF is needed to achieve sufficient prolonged&#xD;
      contact with oral mucosa. The present project aims at employing EGF as therapeutic agent for&#xD;
      mucositis dealing with the challenges of delivery of such macromolecule to the oral mucosa by&#xD;
      using self-healing gels to maximize the drug effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Containers supplied for groups I and II will be identical and will be supplied by a third party pharmacist not a member of this study to ensure participant and patient blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The European Organization for Research and Treatment of Cancer Quality of Life questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Questionnaire developed to assess the quality of life of cancer patients. The questionnaire used will be for that for head and neck patients (EORTC QLQ - H&amp;N43) https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-HN43-English.pdf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO grade of mucositis</measure>
    <time_frame>Baseline</time_frame>
    <description>Grade 1 Soreness, with or without erythema&#xD;
Grade 2 Erythema, ulcers; still able to swallow solid foods&#xD;
Grade 3 Ulcers with extensive erythema; unable to swallow solid foods&#xD;
Grade 4 Ulcers with extensive erythema; alimentation not possible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The European Organization for Research and Treatment of Cancer Quality of Life questionnaire</measure>
    <time_frame>After 7 days of treatment</time_frame>
    <description>Questionnaire developed to assess the quality of life of cancer patients. The questionnaire used will be for that for head and neck patients (EORTC QLQ - H&amp;N43) https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-HN43-English.pdf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO grade of mucositis</measure>
    <time_frame>After 7 days of treatment</time_frame>
    <description>Grade 1 Soreness, with or without erythema&#xD;
Grade 2 Erythema, ulcers; still able to swallow solid foods&#xD;
Grade 3 Ulcers with extensive erythema; unable to swallow solid foods&#xD;
Grade 4 Ulcers with extensive erythema; alimentation not possible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The European Organization for Research and Treatment of Cancer Quality of Life questionnaire</measure>
    <time_frame>After 14 days of treatment.</time_frame>
    <description>Questionnaire developed to assess the quality of life of cancer patients. The questionnaire used will be for that for head and neck patients (EORTC QLQ - H&amp;N43) https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-HN43-English.pdf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO grade of mucositis</measure>
    <time_frame>After 14 days of treatment.</time_frame>
    <description>Grade 1 Soreness, with or without erythema&#xD;
Grade 2 Erythema, ulcers; still able to swallow solid foods&#xD;
Grade 3 Ulcers with extensive erythema; unable to swallow solid foods&#xD;
Grade 4 Ulcers with extensive erythema; alimentation not possible</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>EGF loaded Hydrogel (Gp I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrogel alone ( Gp II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Gp III)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>30 patients will receive the standard of care treatment (Control) which includes benzydamine mouthwash, increased hydration, topical analgesics and antifungals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF loaded Hydrogel</intervention_name>
    <description>Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week</description>
    <arm_group_label>EGF loaded Hydrogel (Gp I)</arm_group_label>
    <other_name>Epidermal Growth Factor-loaded Hydrogel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrogel</intervention_name>
    <description>Non-medicated self-healing hydrogel to be applied three times a day for 1 week</description>
    <arm_group_label>Hydrogel alone ( Gp II)</arm_group_label>
    <other_name>Self-healing Hydrogel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients are those over 18 years of age with WHO grade 3 or 4 oral mucositis&#xD;
             receiving radio- or chemotherapy as treatment for head and neck cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies or those with known allergic reactions to the&#xD;
             drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Basma AA Zakaria, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer at the Faculty of Dentistry - Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noha A Azab, PhD</last_name>
    <phone>01001381954</phone>
    <email>noha.adel@dentistry.cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mai Zakaria, PhD</last_name>
    <email>noha.adel@dentistry.cu.edu.eg</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Basma Elsaadany</investigator_full_name>
    <investigator_title>Lecturer of oral medicine and periodontology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

